Reaction
Sialoadenitis reporting signals
As of the last recalculation, Sialoadenitis appears in 1,340 FAERS reports alongside 24 co-occurring drug terms. The strongest observed disproportionality signal is MEMANTINE (PRR 31.3).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Memantine | 27 | 31.3 | 31.3 |
| Memantine Hydrochloride | 27 | 31.3 | 31.3 |
| Meclizine Hcl 12.5Mg | 15 | 17.3 | 17.3 |
| Meclizine Hcl 25Mg | 15 | 17.3 | 17.3 |
| Meclizine Hcl 12.5 Mg | 15 | 17.3 | 17.3 |
| Meclizine Hcl 25 Mg | 15 | 17.3 | 17.3 |
| Meclizine | 17 | 16.4 | 16.4 |
| Anastrozole Tablets | 21 | 15.4 | 15.4 |
| Temozolomide | 20 | 15.0 | 15.0 |
| Meclizine Hydrochloride | 17 | 13.6 | 13.7 |
| Clindamycin | 23 | 12.8 | 12.8 |
| Ipilimumab | 29 | 10.6 | 10.7 |
| Nivolumab | 63 | 10.6 | 10.6 |
| Anastrozole | 24 | 10.3 | 10.3 |
| Adrenalinum | 27 | 10.3 | 10.3 |
| Donepezil Hydrochloride | 22 | 9.5 | 9.5 |
| Iohexol | 5 | 9.4 | 9.4 |
| Durvalumab | 9 | 6.9 | 6.9 |
| Azacitidine For | 8 | 6.9 | 6.9 |
| Azacitidine | 12 | 6.3 | 6.3 |
| Pembrolizumab | 38 | 5.7 | 5.7 |
| Atezolizumab | 11 | 4.4 | 4.4 |
| Ixekizumab | 7 | 2.9 | 2.9 |
| Guselkumab | 6 | 2.6 | 2.6 |